567 related articles for article (PubMed ID: 16702180)
21. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
[TBL] [Abstract][Full Text] [Related]
22. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
25. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH;
Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432
[TBL] [Abstract][Full Text] [Related]
26. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Kewalramani T; Zelenetz AD; Nimer SD; Portlock C; Straus D; Noy A; O'Connor O; Filippa DA; Teruya-Feldstein J; Gencarelli A; Qin J; Waxman A; Yahalom J; Moskowitz CH
Blood; 2004 May; 103(10):3684-8. PubMed ID: 14739217
[TBL] [Abstract][Full Text] [Related]
27. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
28. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Vellenga E; van Putten WL; van 't Veer MB; Zijlstra JM; Fibbe WE; van Oers MH; Verdonck LF; Wijermans PW; van Imhoff GW; Lugtenburg PJ; Huijgens PC
Blood; 2008 Jan; 111(2):537-43. PubMed ID: 17971487
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
[TBL] [Abstract][Full Text] [Related]
30. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
Lignon J; Sibon D; Madelaine I; Brice P; Franchi P; Briere J; Mounier N; Gisselbrecht C; Faure P; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):262-9. PubMed ID: 20709662
[TBL] [Abstract][Full Text] [Related]
31. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
[TBL] [Abstract][Full Text] [Related]
32. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
[TBL] [Abstract][Full Text] [Related]
35. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
[TBL] [Abstract][Full Text] [Related]
36. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
37. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
Aurer I; Nemet D; Mitrović Z; Dujmović D; Bašić-Kinda S; Radman I; Sertić D; Šantek F; Kralik M; Dotlić S; Mazić S; Labar B
Ann Hematol; 2016 Jun; 95(7):1129-36. PubMed ID: 27103009
[TBL] [Abstract][Full Text] [Related]
38. Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
Menzel H; Müller A; Von Schilling C; Licht T; Peschel C; Keller U
Leuk Lymphoma; 2008 Jul; 49(7):1337-44. PubMed ID: 18604723
[TBL] [Abstract][Full Text] [Related]
39. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
40. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
